Inclusion body myositis.
Inclusion body myositis (IBM) is an inflammatory myopathy with distinctive clinicopathologic features. The etiology of IBM remains elusive. The immune-mediated basis for this disease has been challenged by evidence implicating a number of divergent etiologic factors. These factors include mitochondrial deletions, nitric oxide induced oxidative stress, myonuclear breakdown, and abnormal accumulation within muscle fibers of brain-specific Alzheimer type proteins. The treatment of IBM with conventional immunosuppressive agents has been disappointing. Therapeutic approaches currently under study or consideration are beta-interferon and synthetic anabolic hormones.
Tawil
Rabi
R
Department of Neurology, University of Rochester, Rochester, New York 14642, USA. Rabi_Tawil@urmc.rochester.edu
Griggs
Robert C
RC
D005260:Female; D006801:Humans; D007107:Immune System / Q000503:physiopathology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018979:Myositis, Inclusion Body / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D012737:Sex Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents